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Objectives: Portal vein embolization (PVE) can facilitate the resection of previously unresectable col-
orectal cancer (CRC) liver metastases. Bevacizumab is being used increasingly in the treatment of
metastatic CRC, although data regarding its effect on post-embolization liver regeneration and tumour
growth are conflicting. The objective of this observational study was to assess the impact of pre-
embolization bevacizumab on liver hypertrophy and tumour growth.
Methods: Computed tomography scans before and 4 weeks after PVE were evaluated in patients who
received perioperative chemotherapy with or without bevacizumab. Scans were compared with scans
obtained in a control group in which no PVE was administered. Future liver remnant (FLR), total liver
volume (TLV) and total tumour volume (TTV) were measured. Bevacizumab was discontinued  4 weeks
before PVE.
Results: A total of 109 patients and 11 control patients were included. Portal vein embolization induced
a significant increase in TTV: the right lobe increased by 33.4% in PVE subjects but decreased by 34.8%
in control subjects (P < 0.001), and the left lobe increased by 49.9% in PVE subjects and decreased by
33.2% in controls (P = 0.022). A total of 52.8% of the study group received bevacizumab and 47.2% did
not. There was no statistical difference between the two chemotherapy groups in terms of tumour growth.
Median FLR after PVE was similar in both groups (28.8% vs. 28.7%; P = 0.825).
Conclusions: Adequate liver regeneration was achieved in patients who underwent PVE. However,
significant tumour progression was also observed post-embolization.
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Introduction
Colorectal cancer is diagnosed in approximately 142 570 Ameri-
cans annually.1 Of these, 51 370 will die from the disease.1
Metastasis is the most common cause of death and occurs in the
majority of patients.2,3 In recent decades, outcomes in patients with
colorectal liver metastases (CRLM) have improved as a result of
enhancements in chemotherapy and hepatic resection.4 In selected
patients, the combination of chemotherapy and resection has
increased 5-year survival to up to 50%, comparedwith only 10% in
patients treated with chemotherapy alone.5,6 Perioperative chemo-
therapy regimens for patients with CRLM are based on either
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oxaliplatin or irinotecan. Bevacizumab, a human monoclonal
antibody and an inhibitor of vascular endothelial growth factor
(VEGF), has become part of first-line chemotherapy.7 VEGF plays
a major role in tumour angiogenesis and is required for both
tumour proliferation and healing of injured tissue. Randomized
controlled trials have demonstrated that the addition of bevaci-
zumab to standard chemotherapy increases tumour response,
resectability rate and progression-free survival compared with
chemotherapy alone.8–11
Unfortunately, despite the downsizing effect of preoperative
chemotherapy, the majority of patients still have unresectable
disease. The size of the future liver remnant (FLR) plays a major
role in determining resectability. Therefore, strategies aimed at
increasing the FLR if it is estimated to represent< 20–30%of organ
size (in the absence of chronic liver disease) must be developed.
Preoperative portal vein embolization (PVE) has been shown to be
a safe and effective method of stimulating liver hypertrophy,
increasing FLR and reducing post-hepatectomy complications.12–15
The regenerative process following PVE mirrors the regenera-
tion stimulated after partial hepatectomy. Recent literature sup-
ports the safety of using preoperative chemotherapy in liver
regeneration following PVE.16–18 Despite its increasing clinical
usage, however, there are currently very few data regarding the
effect of bevacizumab on liver regeneration after PVE.17 Moreover,
the potential effect of PVE on tumour growth has been a subject of
concern. In fact, some studies have suggested that, aswell as causing
hypertrophy of normal liver parenchyma, PVE also stimulates the
growth of any tumour that is still present within the regenerating
liver, including embolized and non-embolized sides.19–25
It is evident that the progression of tumours secondary to PVE
could potentially affect resectability and overall survival in patients
with CRLM.Any effect of pre-embolization chemotherapy on this
potential tumour growth would therefore be an important clinical
consideration. Therefore, the objectives of this observational study
were to assess the effect of PVE on the volume of existing CRLM
and to evaluate the effect of pre-embolization therapy, particularly
the use of bevacizumab, on the volumes of metastases and FLR.
Materials and methods
Guidelines for meeting STROBE (strengthening the reporting of
observational studies in epidemiology) criteria were used in the
preparation of this manuscript.
Patients
This study was authorized by the Director of Professional Ser-
vices at the McGill University Health Center as per institutional
protocol. All patients who underwent PVE in preparation for
liver resection (trisegmentectomy or staged resection, according
to tumour board recommendations) were identified. The criteria
for PVE were an FLR of < 30% or staged resection. Between
January 2003 and May 2011, 168 patients underwent PVE; 127 of
these had a diagnosis of CRLM and 41 had alternative diagnoses.
Of the 127 CRLM patients, 18 were excluded because computed
tomography (CT) scans were missing; therefore comparative
volumes could be calculated in 109 patients. Only 89 of the 109
patients could be assigned to the bevacizumab and non-
bevacizumab groups with certainty because some patients had
received chemotherapy in other institutions (Fig. 1). Patients
were also excluded if they had not received preoperative chemo-
therapy or were known to have biliary obstruction or cirrhosis.
Basic demographic data, disease characteristics, surgery and che-
motherapy data were reviewed retrospectively. To assess the
effects of pre-embolization chemotherapy, the study group was
subdivided into those who had received bevacizumab prior to
embolization (n = 47) and those who had not (n = 42). A control
group of patients with CRLM who had not undergone PVE was
identified (n = 11). Control patients were selected if they had
received neoadjuvant chemotherapy, had two CT scans both per-
formed off-chemotherapy and before surgical resection, and if
the time between scans was comparable with the corresponding
interval in the PVE population.
Portal vein embolization
Portal vein embolization was administered prior to a planned
trisegmentectomy or as part of a staged liver resection. The
procedure was performed via an ipsilateral approach using
90–180-mm polyvinyl alcohol (PVA) particles and coils to occlude
segmental branch origins. In patients undergoing right-sided
embolization, the first embolization included both the anterior
and posterior branches of the right portal vein. Patients who failed
to achieve the recommended FLR underwent a subsequent embo-
lization of any remaining segments in the right liver with or
without embolization of segment IV branches. In general, stan-
dard chemotherapy alone was discontinued approximately
4 weeks prior to embolization, and regimens including bevaci-
zumab were discontinued 6 weeks prior to embolization.
Volumetry
To obtain volumetric data, pre- and post-PVE CT scans were
analysed using GE Medical Systems Advantage Windows 4.3
workstations (GE Healthcare, Chalfont St Giles, UK) with dedi-
cated three-dimensional volume calculation software. Two radi-
ologists were blinded to the patients’ chemotherapy treatment.
The volume of the FLR and total liver volume (TLV) were mea-
sured on the portal phase of thin-slice helical CT scans. Routine
scans were performed prior to PVE and 3–4 weeks after PVE. The
ratio between the FLR and TLV was determined before and after
PVE and the absolute difference between these two ratios was
defined as the degree of hypertrophy. Total tumour volumes
(TTVs) and tumour volumes (TVs) in both embolized and
non-embolized lobes were measured in all patients pre- and
post-embolization.
Statistics
Statistical analyses were performed using jmp Version 8.0 (SAS
Institute, Inc., Cary, NC, USA). Normally distributed data
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were expressed as means and standard deviations; otherwise
medians and ranges (interquartile ranges) were used. Nominal
data were expressed as percentages. Differences in tumour
growth against PVE and the use of bevacizumab were estab-
lished using paired t-tests or Mann–Whitney U-tests as appro-
priate for continuous data. The chi-squared test was used for
nominal data. Between-group differences were considered statis-
tically significant at P < 0.05.
Results
Patients
A total of 127 CRLM patients who underwent PVE prior to liver
resection were initially identified. Patients were excluded from the
study group if they lacked two CT scans for volumetric calcula-
tions and thus 109 patients remained for tumour volume analysis
(Fig. 1). Eleven control patients with two appropriately timed CT
scans were also identified.
Patient demographics and preoperative variables are shown
in Table 1. Among the 109 patients who received pre-
embolization chemotherapy, receipt of bevacizumab was con-
firmed in 89 patients, 47 (52.8%) of whom were given
pre-embolization bevacizumab. Complete details of the chemo-
therapy regimen were missing for some patients (Fig. 1)
because they had been treated at a different institution. Chemo-
therapy was oxaliplatin-based in 22 and 17 patients in the beva-
cizumab and non-bevacizumab groups, respectively, and
irinotecan-based in 13 and 12 patients in the bevacizumab
and non-bevacizumab groups, respectively. One patient in the
bevacizumab group and two in the non-bevacizumab group
received chemotherapy using both oxaliplatin and irinotecan.
Patients received a median of six (range: five to nine) chemo-
therapy cycles prior to embolization and the median time inter-
val for all patients was 70 days (interquartile range: 51–100
days). Sixty patients (67.4%) underwent resection, including 30
patients (63.8%) in the bevacizumab group and 30 (71.4%) in
the non-bevacizumab group (P = 0.167).
Portal vein embolization
Baseline characteristics and embolization data for patients who
underwent PVE, by chemotherapy group (bevacizumab and non-
bevacizumab), compared with those who did not undergo PVE,
are shown in Table 1. In total, 105 patients (96.3%) underwent a
right-sided embolization and four patients, all in the bevacizumab
group, underwent segment IV and right portal vein embolization.
One of these four patients had an extended right hepatectomy.
ALL patients who underwent PVE
during 2003−2011
n = 168
Patients diagnosed with colorectal cancer liver metastases
n = 127
Patients with calculated tumour volumes
n = 109
Patients lacking a complete set
of computed tomography scans
n = 18
Patients lacking complete
chemotherapy data
n = 20
Patients with chemotherapy data
n = 89
11 Hepatocellular carcinoma
14 Cholangiocarcinoma
6   Neuroendocrine tumour
2   Breast cancer liver metastases
2   Renal cell carcinoma liver metastases
2   Melanoma liver metastases
1   Sarcoma liver metastases
1   Parotid cancer liver metastases
1   Haemangioma
1   Unknown primary
n = 41
Figure 1 Distribution of patients who underwent portal vein embolization (PVE) during 2003–2011
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The median FLR in the 109 patients with CRLM who under-
went PVE was 21.7% (range: 15.9–26.3%) before embolization
and 28.7% (range: 23.2–35.4%) after embolization (P < 0.001).
The median degree of hypertrophy was 6.0 (range: 1.6–10.2).
Tumour volumes
Overall, 77.1% of patients had an increase in TV. Statistically
significant increases in TV were seen in both liver lobes (Tables 2
and 3); changes in TV in the PVE group differed markedly from
those in the control group of patients who did not undergo PVE.
Patients in the PVE group demonstrated a 33.4% increase in TV in
the right lobe, whereas control subjects showed a 34.8% decrease
in TV in the right lobe (P < 0.001). These percentages corre-
sponded to a positive growth rate of 0.07 cm3/day (range:
0–0.27 cm3/day) in the PVE group and a negative rate of 0.06
cm3/day (range: 0.18–0.01 cm3/day) in the controls (P < 0.001).
Patients in the PVE group showed an increase in TV of 49.9% in
the left lobe, whereas control subjects demonstrated a decrease in
TV of 33.2% in the left lobe (P = 0.022). Eight patients in the PVE
group demonstrated unilateral disease on the first CT scan and
developed new lesions on the second CT scan (i.e. after PVE), an
event that was not observed in any patient in the control group.
This difference did not reach statistical significance (P = 0.427).
The effects of pre-embolization chemotherapy in the bevaci-
zumab and non-bevacizumab groups on tumour growth after
PVE are shown in Tables 4 and 5. The percentage increase in
tumour growth was higher in the non-bevacizumab group than in
the bevacizumab group, but the difference was not statistically
significant. Rates of tumour growth in the non-bevacizumab
and bevacizumab groups, respectively, were 56.2% vs. 34.5%
(P = 0.764) in the right lobe, and 54.3% vs. 30.1% (P = 0.612) in
the left lobe.
Table 1 Baseline characteristics in the total study population
PVE No PVE P-value
Bev (n = 47) Non-bev (n = 42) Bev (n = 11)
Male, n (%) 26 (55.3) 28 (66.7) 9 (81.8) 0.191
Primary tumour, n (%)
Colon 33 (70.2) 28 (66.7) 6 (54.5) 0.042a
Rectum 6 (12.8) 12 (28.6) 5 (45.5)
Missing data 8 (17.0) 2 (4.8) 0
Lesions, n (%)
Synchronous 37 (70.2) 37 (88.1) 7 (63.6) 0.051
Metachronous 3 (6.4) 3 (7.1) 3 (27.3)
Missing data 7 (14.9) 2 (4.8) 1 (9.1)
Chemotherapy cycles, median (range) 6.0 (5–9) 7.5 (6–9) 7.0 (6–16) 0.266
Chemotherapy regimen, n (%)
Oxaliplatin-based 22 (46.8) 17 (40.4) 5 (45.5) 0.701
Irinotecan-based 13 (27.7) 12 (28.6) 2 (18.2) 0.701
Both 1 (2.2) 2 (4.8) 0
Missing 11 (23.3) 11 (26.2) 4 (36.3)
Resected, n (%) 30 (63.8) 30 (71.4) 10 (90.9) 0.167
Staged 18 (60.0) 15 (50.0) 2 (20.0) 0.316
Trisegmentectomy 12 (40.0) 15 (50.0) 8 (80.0)
Right-sided embolization, n (%) 46 (97.8) 41 (97.6) NA
Segment IV embolizationb, n (%) 4 (8.5) 0 NA
Resected 1 (25.0)
Unresectable 2 (50.0)
Missing 1 (25.0)
Days between CT scans, median (range) 72 (52–116) 65 (51–117) 68 (47–92) 0.581
Days from chemotherapy to second CT scan, median (range) 51 (30–107) 44 (27–100) 70 (47–116) 0.220
aThere were more cases of rectal cancer in the control group; no difference was seen when comparing bev vs. non-bev in the PVE group (P = 0.179).
bRight-sided and segment VI embolization.
PVE, portal vein embolization; bev, bevacizumab; CT, computed tomography; NA, not available.
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Liver regeneration after PVE
A clinically significant increase in FLR volume was observed in
both groups after PVE. Both groups had similar TLV prior to
(P = 0.617) and after (P = 0.581) embolization.
The addition of bevacizumab to chemotherapy did not affect
the pre- to post-embolization change in FLR volume. The propor-
tion of the FLR increased from 20.8% to 28.8% in the bevaci-
zumab group, and from 21.3% to 28.7% in the non-bevacizumab
group (P = 0.825). Correspondingly, the mean degree of hyper-
trophy was comparable in the two groups (Table 6).
Correlation of the percentage growth in the FLR with the per-
centage growth in TV revealed a statistically significant positive
Table 2 Tumour volumetry in the right lobe in patients who did and did not undergo portal vein embolization (PVE)
PVE (n = 109) No PVE (n = 11) P-value
Tumour volume, cm3, median (range)
First CT scana 21.2 (4.5–76.4) 10.6 (3.2–14.8) 0.080
Second CT scan 34.8 (11.5–112) 6.6 (2.0–9.9) < 0.001
P-valueb < 0.001 0.002
Change in tumour volume, % (range) 33.4 (- 0.5 to 168.0) - 34.8 (- 40.7 to - 26.1) < 0.001a
aTumour volumes calculated from first and second CT scans (with embolization during interval time for study group only).
bDifference between pre- and post-embolization values.
CT, computed tomography.
Table 3 Tumour volumetry in the left lobe in patients who did and did not undergo portal vein embolization (PVE)
PVE (n = 109) No PVE (n = 11) P-value
Tumour volume, cm3, median (range)
Pre-PVE 0 (0–3.2) 0 (0–7.4) 0.694
Post-PVE 0 (0–6.0) 0 (0–3.6) 0.805
P-value < 0.001 0.625
Change in tumour volumea, % (range) 49.9 (- 24.2 to 118.0) - 33.2 (- 58.0 to 6.0) 0.022
New bilateral diseaseb, n (%) 8 (7.3) 0 0.595
aDifference in tumour volumes in the left lobe between patients receiving PVE and control subjects, expressed as a percentage.
bNew lesions in the left lobe on the second computed tomography scan (i.e. after embolization in the PVE group).
Table 4 Tumour volumetry in the right lobe in patients who underwent portal vein embolization (PVE) with and without bevacizumab (bev)
Bev (n = 47) Non-bev (n = 42) P-value
Tumour volume, cm3, median (range)
Pre-PVE 16.4 (3–75.5) 22.4 (6.2–65.5) 0.370
Post-PVE 21.2 (8.4–82.6) 33.7 (11.7–117.0) 0.255
P-value 0.003 < 0.001
Change in tumour volumea, % (range) 34.5 (- 2.5 to 212.2) 56.2 (3.6–165.0) 0.764
aChange in tumour volumes in the right lobe, expressed as a percentage, in patients who did and did not receive bevacizumab (all received PVE).
Table 5 Tumour volumetry in the left lobe in patients who underwent portal vein embolization (PVE) with and without bevacizumab (bev)
Bev (n = 47) Non-bev (n = 42) P-value
Tumour volume, cm3, median (range)
Pre-PVE 0 (0–3.3) 0 (0–2.6) 0.435
Post-PVE 0 (0–5.2) 0 (0–5.6) 0.654
P-value 0.123 0.021
Change in tumour volumea, % (range) 30.1 (- 62.4 to 190.6) 54.3 (- 23.9 to 100.1) 0.612
aChange in tumour volumes in the left lobe, expressed as a percentage, in patients who did and did not receive bevacizumab (all received PVE).
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linear correlation between the growth of the remnant liver and the
growth of tumours in the right lobe of the liver (P = 0.043)
(Fig. 2).
Discussion
Portal vein embolization is an important strategy in the optimi-
zation of resectability rates in CRLM and is reported to be safe and
effective in stimulating contralateral liver growth, which can be a
major limitation in the resectability of CRLM. There are concerns
that PVE may simultaneously stimulate tumour growth and this
may limit its use. This study has demonstrated that PVE stimu-
lates tumour growth in both embolized and non-embolized lobes
of the liver compared with control lobes in a group of patients
who had not received PVE and had been off preoperative chemo-
therapy for a duration similar to that of the PVE patients. The
addition of bevacizumab to chemotherapy administered before
embolization trended towards a relative protective effect
(although this did not reach statistical significance), reducing this
enhanced tumour growth without affecting liver hypertrophy. To
the authors’ knowledge, this is the largest study to demonstrate
the effects of PVE on liver hypertrophy and tumour growth in
patients with CRLM.
Bevacizumab has been shown to improve pathologic response
rates when combined with cytotoxic agents and has also been
reported to exert a protective effect against sinusoidal injuries
induced by oxaliplatin-based chemotherapy.26 Nevertheless, the
inclusion of bevacizumab in treatment regimens for patients
scheduled to undergo PVE and hepatic resection has been tem-
pered by concerns regarding impaired wound healing and tissue
regeneration, both of which are greatly dependent on angiogenesis
and VEGF expression. Consistent with findings by Gruenberger
and colleagues,27 the present study found no increased risk for
morbidity post-resection in patients receiving perioperative che-
motherapy with bevacizumab.28 However, existing data regarding
the effects of bevacizumab on post-embolization hypertrophy
remain scarce and inconsistent.29,30 In a retrospective study con-
ducted at theMDAnderson Center, University of Texas, preopera-
tive chemotherapy plus bevacizumab did not impair liver
regeneration after PVE.29 Patients included in that study received
oxaliplatin-based chemotherapywith (n= 26;median six cycles) or
without (n = 17; median five cycles) bevacizumab, or received no
chemotherapy before embolization (n = 22). After a median of
4 weeks post-PVE, no significant difference in the degree of hyper-
trophy was found among patients who had no chemotherapy,
patients who received chemotherapy with bevacizumab and
patients who received chemotherapy without bevacizumab (mean
values 10.0%, 8.8% and 6.8%, respectively; P = 0.11). Conversely,
Aussilhou and colleagues30 reported a significantly smaller increase
in mean FLR volume in 13 patients receiving bevacizumab plus
standard chemotherapy compared with 26 patients treated with
chemotherapy only (561 cm3 vs. 667 cm3; P < 0.03).30 In that study,
30% of patients underwent portal vein ligation instead of embo-
lization. Importantly, themean number of bevacizumab cycles was
12, and the number of cycles above six was found to significantly
reduce liver growth, as was age  60 years. It is noteworthy that
prolonged chemotherapy has been identified previously as a factor
contributing to impaired liver regeneration.31,32
In the present study, patients received a median of six chemo-
therapy cycles (five to nine in the bevacizumab group; six to nine
in the non-bevacizumab group). This is consistent with the dura-
tion of treatment in the MD Anderson study.29 Volumetric CT
assessments were completed within 3–4 weeks after PVE in the
present study; this is in concordance with published data showing
Table 6 Liver volumetry by chemotherapy group in patients who underwent portal vein embolization (PVE) with and without bevacizumab
(bev)
Bev (n = 47) Non-bev (n = 42) P-value
Total liver volume, cm3, median (range)
Pre-PVE 1588 (1444–2000) 1685 (1377–2073) 0.617
Post-PVE 1635 (1415–2037) 1766 (1385–2135) 0.581
Future liver remnant, %, median (range)
Pre-PVE 20.8 (15.1–23.8) 21.3 (14.9–26.4) 0.373
Post-PVE 28.8 (21.9–34.5) 28.7 (24.8–35.7) 0.825
Degree of hypertrophy 7.5 (3.4–11.2) 5.1 (1.0–12.5) 0.127
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that the greatest increase in post-embolization liver volume
(about 75%) occurs within 3 weeks after the procedure and is
followed by a plateau phase of minimal regeneration.33
The progression of metastases after embolization was first
described by Elias et al., who showed that four of five patients had
tumour growth after PVE.20 However, that study included a small
number of patients, lacked a control group and included patients
with heterogeneous liver pathologies. In 2001, Kokudo et al.
evaluated tumour proliferation after PVE using the Ki-67 labelling
index, and showed that PVE induced a higher rate of proliferation
compared with that in PVE-free controls.19 Although these
authors included more patients (18 patients in the study group
and 29 controls), there was no mention of peri-embolization che-
motherapy. In 2007, Ribero et al. observed no changes in tumour
size in 80 patients undergoing PVE.22 The authors did not,
however, report the proportions of patients in whom tumour size
increased or decreased and measured tumour diameters rather
than volumes. It is the present authors’ belief that tumour volume
measurements are more accurate, especially when metastatic
lesions are numerous, heterogeneous and uneven.
In the current study, significant increases in median TV were
observed in both liver lobes (33.4% and 49.9% in the right and left
lobes, respectively) in the PVE population, compared with the
control group (decreases of 34.8% and 33.2% in the right and left
lobes, respectively). Growth within the left lobe would potentially
have more impact on resectability and therefore patient survival.
The current study included eight patients (7.3%) who developed
new lesions within the remnant liver lobe after embolization,
seven of whom were rendered unresectable. None of the patients
in the control group developed new lesions within the left lobe
during the time interval between the scans. This difference is of
major clinical significance as it may have an impact on patient
survival. These results suggest that metastases that respond to
chemotherapy continue to do so for some time after chemo-
therapy is stopped and that the regenerative milieu stimulated by
the PVE is of a magnitude that reverses this effect. The fact that
new lesions appear in some patients may indicate that microme-
tastases are being recruited in this regenerative environment.
Additionally, the current study demonstrated that patients who
underwent PVE and who received pre-embolization bevacizumab
had less pronounced overall tumour progression than patients
who received chemotherapy only. However, this difference did not
reach statistical significance. The addition of bevacizumab has
been shown to improve pathologic response, as evidenced by a
significant reduction in viable tumour cells and an increase in
tumour fibrosis, resulting in a protective effect against sinusoidal
injuries induced by oxaliplatin-based chemotherapy.34–36 The
increased response rate and/or fibrosis may explain the less pro-
nounced growth observed in the bevacizumab group after PVE. A
prospective examination of pathology specimens is needed to
confirm this theory.
The limitations of the current study are those inherent to ret-
rospective analyses and make it impossible to make specific rec-
ommendations regarding treatment regimens. Prospective studies
with homogeneous populations would be required to assess the
optimal type and timing of treatment regimens in relation to PVE
in patients with CRLM. Prospective studies are also required to
assess the impact of PVE-induced tumour growth on outcomes
such as resectability and longterm survival. In general, a single CT
scan is performed between the end of chemotherapy and liver
resection at this institution, which explains the relatively small
number of control patients who underwent two CT scans between
the cessation of chemotherapy and surgery.
In conclusion, the current study reports on the effects of pre-
embolization bevacizumab on liver regeneration and tumour
growth observed after PVE in the largest cohort of patients
studied to date. These findings provide evidence that PVE induces
significant tumour growth in patients with CRLM.Although PVE
is an essential tool in the management of CRLM, its effectiveness
can be enhanced by developing strategies that limit tumour
growth without suppressing liver regeneration.
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